Business
Final Results and Notice of AGM
Final Results and Notice of AGM.
About this update from Physiomics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5021A\n Physiomics PLC\n 30 September 2020\n \n \n \n \n 30 September 2020\n \n \n \n \n \n Physiomics plc\n \n \n (\"Physiomics\" or \"the Company\")\n \n \n Final Results for the year ended 30 June 2020 and Notice of AGM\n \n Highlights\n \n Financial Highlights\n \n • Total income (revenue and grant income) increased 7% to £841,649 (2019: £783,101), the highest in the Company's history\n \n • The operating loss decreased 33% to £134,385 (2019: £201,219)\n \n • The loss after taxation decreased 38% to £64,424 (2019: £104,040)\n \n • Placing and subscription in May 2020 raised £828,750 (gross) through the issue of 23,678,571 new ordinary shares at an issue price of 3.5 pence per share\n \n • At 30 June 2020, the surplus of shareholders' funds was £1,314,981 (30 June 2019: £607,914)\n \n • Cash and cash equivalents at 30 June 2020 of £1,047,860 (30 June 2019: £405,366)\n \n Operational highlights\n \n • Renewal of agreement with Merck KGaA in December 2019\n \n • Repeat contracts with clients CellCentric and Bicycle Therapeutics\n \n • Award of NIHR grant to fund clinical study relating to Physiomics' personalised dosing tool for prostate cancer and ongoing discussion relating to its commercialisation\n \n • Post period end, award of contract by new big-pharma client, Astellas Pharma Inc\n \n • Ongoing discussion with several large CROs relating to potential collaborations\n \n • Strongest ever business development pipeline resulting from higher marketing spend\n \n Dr Paul Harper, Non-Executive Chairman, commented:\n \n \"The Company continues to make good progress, with all key indicators of performance moving in the right direction. We are pleased to be working with Cancer Research UK (announced July 2019) and to have repeat contracts with both CellCentric and Bicycle Therapeutics, as well as our first contract with Astellas Pharma Inc.\n \n The team has also worked hard to ensure that our on-going relationship with Merck led to a renewal of the arrangement (first announced in December 2017). We believe that the Merck team recognises the quality and value of our modelling itself, coupled with the interpretation and guidance we are able to provide. The relationship with Merck represents an independent endorsement of the quality of ...